Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note issued to investors on Friday,Benzinga reports. They currently have a $15.00 price target on the stock.

Several other equities research analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, March 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Stock Down 7.9%

Shares of COYA opened at $4.17 on Friday. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.75. The firm’s fifty day moving average is $4.55 and its two-hundred day moving average is $5.33. The stock has a market cap of $97.83 million, a PE ratio of -3.28 and a beta of 0.51.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The business had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million. As a group, research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in shares of Coya Therapeutics during the 3rd quarter valued at about $28,000. CIBC Private Wealth Group LLC purchased a new stake in Coya Therapeutics in the 4th quarter valued at about $47,000. Occudo Quantitative Strategies LP purchased a new stake in Coya Therapeutics in the 4th quarter valued at about $66,000. Lantern Wealth Advisors LLC purchased a new stake in Coya Therapeutics in the 3rd quarter valued at about $66,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in Coya Therapeutics in the 4th quarter valued at about $81,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.